# A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)

> **NCT00403403** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 102 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Chemotherapy
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00403403
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2009-02
- **Final completion:** 2009-06
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2011-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00403403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00403403, "A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00403403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*